Case Report
===========

Clinical Presentation
---------------------

A dichorionic diamniotic male twin was born at 35 weeks of gestation with a birth weight of 1.6 kg (small for gestational age). The baby presented with recurrent hypoglycemia shortly after birth. Blood tests on the second day of life showed cholestasis (up to 145 umol/L), hypoalbuminemia, hyperammonemia (up to 453 umol/L), and coagulopathy, which progressively worsened throughout the first week of life. Work-up for neonatal liver failure was negative for metabolic disease, and surgical and infective causes.

Ferritin level was elevated at 8,397 umol/L. Biopsy of the liver and buccal mucosa was performed. This demonstrated hepatic and extrahepatic iron deposition ( [Fig. 1](#FI180007-1){ref-type="fig"} ) and confirmed the diagnosis of neonatal hemochromatosis (NH; likely due to gestational alloimmune liver disease, GALD). Medical treatment was given with exchange transfusion and intravenous immunoglobulin (IVIg). However, he failed to respond to medical treatment and developed worsening liver failure. Liver transplantation was considered but deemed not an option due to the low body weight and unavailability of living-related liver donor. After extensive discussion with the parents, the decision for redirection of care was made. The baby was electively extubated and eventually succumbed on day 33 of life.

![Liver biopsy showing hepatocellular siderosis (left) and abnormal iron deposition in salivary gland (right), demonstrating iron in blue by Perl\'s stain.](10-1055-s-0038-1675335-i180007-1){#FI180007-1}

On the contrary, the other twin girl was born with a birth weight of 2.4 kg and suffered only from mildly deranged liver function only. Her liver function test showed mildly elevated liver enzymes (peak aspartate aminotransferase \[AST\] of 371 U/L and alanine aminotransferase \[ALT\] of 162 U/L at around 3 weeks of life) and conjugated bilirubin (11 umol/L), with normal ammonia level and clotting profile all along. Metabolic, surgical, and infective work-ups were negative. Ferritin level was high at 9,801 umol/L. Liver function test subsequently normalized spontaneously upon follow-up.

Family was counseled on the importance of antenatal treatment with IVIg in future pregnancies to prevent the recurrence of NH.

Discussion
==========

Although neonatal liver failure is rarely encountered, one of the most important diagnoses to consider is NH. NH is a rare condition. The exact incidence of the disorder is unknown. Fetal liver injury causes disturbed fetal iron homeostasis, resulting in fetal iron overload. NH is characterized by severe liver injury with the accumulation of iron in hepatic and extrahepatic tissues. The most common cause of fetal liver injury leading to the NH phenotype is a gestational alloimmune disorder called GALD. [@JR180007-1] [@JR180007-2] It results from the transplacental transfer of maternal immunoglobulin G (IgG) directed against an antigen on the fetal hepatocyte, with fetal complement activation and formation of membrane attack complex, resulting in fetal hepatocyte injury and death (with congenital cirrhosis and siderosis of extrahepatic tissues). Once a woman has become sensitized, transplacental passage of IgG can occur in subsequent pregnancy, causing immune-mediated liver injury in the fetus.

Diagnosis of NH is by the demonstration of iron accumulation in the extrahepatic tissues, usually through the biopsy of oral mucosal salivary glands or using T2-weighed magnetic resonance imaging (MRI) demonstrating the accumulation of iron in the pancreas, heart, or adrenal glands. [@JR180007-1] Antibodies to C5b-9 complex, a neoantigen created during the activation of terminal complement cascade, are used to demonstrate the accumulation of membrane attack complex in liver biopsy. [@JR180007-2] However, this immunohistochemical staining for C5b-9 complex is not available in our locality.

Treatment for NH includes exchange transfusion (by removing existing reactive antibodies) and IVIg (blocking antibody action and interfering with complement activation). [@JR180007-3] [@JR180007-4] Survival with medical treatment (without liver transplantation) is reported to be at around 75%. [@JR180007-4] If medical treatment fails, liver transplantation remains to be the last therapeutic option.

NH presentation could be quite heterogeneous, as shown in this pair of twins. The twin boy was being affected antenatally with growth restriction and early presentation with hypoglycemia within few hours after birth followed by liver failure. Without the frank presentation of liver failure in one of the index twin, the other twin would have been managed as a case of neonatal hepatitis, and the diagnosis of NH would be missed. With antenatal IVIg treatment, outcome of future pregnancy in our index family is expected to be good. [@JR180007-5] [@JR180007-6]

[Table 1](#TB180007-1){ref-type="table"} summarizes the clinical characteristics of published cases of twins pregnancy affected by NH in the literature. [@JR180007-7] [@JR180007-8] [@JR180007-9] [@JR180007-10] [@JR180007-11]

###### Summary of twins pregnancy affected by NH

                                  Normal values   Twin set 1 (index)                          Twin set 2 ^7^                        Twin set 3 [@JR180007-8]                                  Twin set 4 [@JR180007-9]   Twin set 5 [@JR180007-9]                         Twin set 6 [@JR180007-10]                         Twin set 7 [@JR180007-11]                               Twin set 8 [@JR180007-11]       
  ------------------------------- --------------- ------------------------ ------------------ ------------------ ------------------ -------------------------------- ------------------------ -------------------------- -------------------------- --------------------- --------------------------- --------------------- -------------------------------- --------------------- -------------------------------- --------------------------------
  **Pregnancy**                                   DCDA                     DCDA               MC                 MC                 MC                               MC                       N/A                        MCDA                       MCDA                  MC                          MC                    DCDA                             DCDA                  DCDA                             DCDA
  **Gender**                                      Male                     Female             Male               Male               Female                           Female                   Male                       Male                       Male                  Male                        Male                  Male                             Female                Female                           Female
  **Gestational age (weeks)**                     35                       35                 37                 37                 34                               34                       27                         26                         26                    33                          33                    35                               35                    37                               37
  **Birth weight (kg)**                           1.6                      2.4                2.49               2.5                1.83                             1.95                     0.92                       0.82                       0.9                   2.4                         2.1                   AGA                              AGA                   AGA                              AGA
  **Total bilirubin (umol/L)**    \<24            368                      169                154                197                36                               N/A                      149                        71                         476                   --                          N/A                   231                              67                    91                               238
  **Direct bilirubin (umol/L)**   \<10            145                      11                 32                 21                 19                               N/A                      N/A                        N/A                        N/A                   --                          N/A                   113                              9                     7                                80
  **AST (U/L)**                   \<60            146                      371                502                133                34                               N/A                      N/A                        N/A                        N/A                   --                          N/A                   N/A                              N/A                   N/A                              N/A
  **ALT (U/L)**                   \<53            56                       162                78                 23                 101                              N/A                      98                         25                         306                   --                          5                     27                               41                    21                               38
  **INR**                         \<2             4.5                      1.2                2.8                1.5                3                                N/A                      1.5                        1.2                        1.6                   --                          1.37                  4.7                              1                     2.2                              3.4
  **Ferritin (pmol/L)**           275--831        8,397                    9,801              62,115             5,643              3,596                            N/A                      2,663                      5,443                      6,625                 --                          1,180                 2,609                            1,539                 3,762                            8,865
  **NH Treatment**                                IVIG, ET                 Not required       IVIG               Not required       Antioxidant--chelation therapy   N/A                      Antioxidant therapy        Not required               Antioxidant therapy   --                          Antioxidant therapy   Antioxidant--chelation therapy   Antioxidant therapy   Antioxidant--chelation therapy   Antioxidant--chelation therapy
  **Outcome**                                     Died on day 33 of life   Healthy at 10 mo   Healthy at 1.5 y   Healthy at 1.5 y   Healthy at 1 y                   Died on day 12 of life   Alive                      Alive                      Alive                 IUD                         Healthy at 6 mo       Healthy at 1 y                   Healthy at 1 y        Healthy at 10 mo                 Healthy at 10 mo

Abbreviations: AGA, appropriate for gestational age; ALT, alanine aminotransferase; AST, aspartate aminotransferase; DCDA, dichorionic--diamniotic; ET, exchange transfusion; INR, international normalized ratio; IUD, intrauterine demise; IVIG, intravenous immunoglobulin; MC, monochorionic; MCDA, monochorionic-diamniotic; N/A, not available; NH, neonatal hemochromatosis .

Conclusion
==========

In conclusion, a high index of suspicion of NH in babies presenting with cholestasis and deranged liver function is important so as to facilitate its early diagnosis and management. It has a high recurrence in subsequent pregnancies, and antenatal IVIg treatment can greatly reduce this chance.
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